(Courageous Discourse) — Far and away the most common questions I receive from followers deal with the issue of acute SARS-CoV-2 viral infection termed COVID-19 illness.
The reason why myself and several other leading doctors prioritized the ambulatory phase of the illness was driven by the observation that the primary endpoint of interest was hospitalization and death. Since most deaths were occurring in the hospital, the prevention of hospitalization largely would be a strategy to improve both outcomes and allow community-dwelling individuals to survive the illness much like any other viral upper respiratory tract illness in the comfort of their homes.
At the very top of the protocol is the quick clinical process of “risk stratification” specifically indicating the risk for hospitalization and death which is not the same for every person.
Additionally, SARS-CoV-2 has substantially mutated through strains: Wuhan wild-type, Alpha, Beta, Gamma, Delta, and Omicron.
At the advent of Omicron, the infection became considerably less virulent. Omicron, however, was the first strain that broke through natural immunity in large numbers creating the opportunity for second and third episodes of COVID-19.
Dr. Peter McCullough has been following his patients carefully in practice and communicating with physicians around the world and their collective observations are cohesive with emerging scientific data with some good news: successive COVID-19 infections are progressively milder. In other words, the natural immunity gained from the first or index infection is protective against severe outcomes with the next infection.
Chemaitelly and colleagues have reported 97 percent protection against hospitalization and death with natural immunity with no waning of protection over time.
Thus, the most important risk stratifier is well-documented prior infection. After that, the conventional risk factors for severe infection can be integrated in any one of the risk calculators.
These factors in approximate descending importance include: age, obesity, lung disease, heart disease, cancer, kidney disease, diabetes, and other chronic illnesses and conditions.
When evaluating a manuscript on COVID-19 outcomes for example with vaccination, look in the table of baseline characteristics (usually Table 1) and see if the authors have disclosed whether or not patients have had a prior episode of COVID-19.
You will be shocked how many manuscripts have been published during the Omicron era without disclosing prior infection as the most important baseline variable. Unfortunately, most of these papers are rendered invalid based on unaccounted confounding. For example, one cannot conclude vaccines or boosters or any other intervention makes COVID-19 “milder” unless the study is randomized or otherwise handles the important confounder of natural immunity.
In Substack posts to follow, the intensity and duration of treatment for COVID-19 in the McCullough Protocol© will be described according to the risk of hospitalization and death.
As a general rule for those initially presenting with mild symptoms, for second and third infections are indistinguishable from the common cold and it is rare that prescription medications are needed provided prompt over-the-counter agents are deployed.
In summary, receiving the next call on acute COVID-19, the first question to ask is: “Is this the first episode of COVID-19, or have you had it before?” If your doctor, employer, school, or military health office is not asking this question — be sure to bring it up and have it documented in the medical record.
Reprinted with permission from Courageous Discourse.